RRPV #RAPID Coming Soon

BARDA RRPV RAPID Program for Antibody Production for Diagnostics (Coming Soon)

BARDA, through its Rapid Response and Preparedness Ventures (RRPV), is preparing a new program to accelerate the development and production of antibodies and protein-based molecular recognition reagents for diagnostic use. - Government Buyer: - Biomedical Advanced Research and Development Authority (BARDA) - Rapid Response and Preparedness Ventures (RRPV) - OEMs and Vendors: - No specific OEMs or vendors are named in this notice - Products/Services Requested: - End-to-end solutions for discovery, development, and production of antibodies and protein-based molecular recognition reagents for diagnostics - Solutions must include: - Generation of high-affinity, high-specificity binders against priority targets - Scalable workflows for producing diagnostic-use quantities - Pathways toward GMP-compatible production - Rapid, reliable delivery of purified, assay-ready reagents within weeks from target identification - Flexible capabilities adaptable to emerging public health threats - Unique/Notable Requirements: - Emphasis on reducing traditional development timelines - Integrated, innovative approaches from discovery through production - No specific products, part numbers, or quantities listed at this stage

Description

The Biomedical Advanced Research and Development Authority (BARDA), through the Rapid Response and Preparedness Ventures (RRPV), will soon release a new program aimed at accelerating the end-to-end development and production of antibodies and other protein-based molecular recognition reagents for diagnostic applications. This program seeks integrated solutions that significantly reduce traditional development timelines, enabling rapid delivery of purified, assay-ready reagents within weeks from target identification. Proposed approaches must demonstrate the ability to generate high-affinity, high-specificity binders and scalable workflows suitable for diagnostic use, with a clear pathway toward GMP-compatible production. The objective is to establish a flexible, rapid capability adaptable to emerging public health threats for timely diagnostic reagent development.

View original listing